Literature DB >> 29117430

Biological false-positive venereal disease research laboratory test in cerebrospinal fluid in the diagnosis of neurosyphilis - a case-control study.

S Zheng1,2, R J Lin3, Y H Chan4, C C L Ngan5.   

Abstract

BACKGROUND: There is no clear consensus on the diagnosis of neurosyphilis. The Venereal Disease Research Laboratory (VDRL) test from cerebrospinal fluid (CSF) has traditionally been considered the gold standard for diagnosing neurosyphilis but is widely known to be insensitive.
OBJECTIVE: In this study, we compared the clinical and laboratory characteristics of true-positive VDRL-CSF cases with biological false-positive VDRL-CSF cases.
METHODS: We retrospectively identified cases of true and false-positive VDRL-CSF across a 3-year period received by the Immunology and Serology Laboratory, Singapore General Hospital. A biological false-positive VDRL-CSF is defined as a reactive VDRL-CSF with a non-reactive Treponema pallidum particle agglutination (TPPA)-CSF and/or negative Line Immuno Assay (LIA)-CSF IgG. A true-positive VDRL-CSF is a reactive VDRL-CSF with a concordant reactive TPPA-CSF and/or positive LIA-CSF IgG.
RESULTS: During the study period, a total of 1254 specimens underwent VDRL-CSF examination. Amongst these, 60 specimens from 53 patients tested positive for VDRL-CSF. Of the 53 patients, 42 (79.2%) were true-positive cases and 11 (20.8%) were false-positive cases. In our setting, a positive non-treponemal serology has 97.6% sensitivity, 100% specificity, 100% positive predictive value and 91.7% negative predictive value for a true-positive VDRL-CSF based on our laboratory definition. HIV seropositivity was an independent predictor of a true-positive VDRL-CSF.
CONCLUSION: Biological false-positive VDRL-CSF is common in a setting where patients are tested without first establishing a serological diagnosis of syphilis. Serological testing should be performed prior to CSF evaluation for neurosyphilis.
© 2017 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29117430     DOI: 10.1111/jdv.14681

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  2 in total

1.  Management of Adult Syphilis: Key Questions to Inform the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines.

Authors:  Susan Tuddenham; Khalil G Ghanem
Journal:  Clin Infect Dis       Date:  2022-04-13       Impact factor: 9.079

2.  Which Is the Optimum Antigen Concentration for the Venereal Disease Research Laboratory Test of Cerebrospinal Fluid for Neurosyphilis Diagnosis: 10 or 17 μL?

Authors:  Yao Xiao; Wei Li; Qiu-Ling Li; Qiu-Yan Xu; Yang Yang; Tian-Ci Yang; Li-Li Liu; Wei-Ming Gu
Journal:  Front Med (Lausanne)       Date:  2022-04-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.